Navigation Links
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
Date:4/15/2008

s a stabilizer accounted for a disproportionate share of the total number.

Glycine, an amino acid, is used as a stabilizer. GAMMAGARD LIQUID does not contain sucrose.

GAMMAGARD LIQUID is made from human plasma. It may carry a risk of transmitting infectious agents, viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Components used in the packaging of this product are latex-free.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Various mild and moderate reactions, such as headache, fever, fatigue, chills, flushing, dizziness, urticaria, wheezing or chest tightness, nausea, vomiting, rigors, back pain, chest pain, muscle cramps, and changes in blood pressure may occur with infusions of Immune Globulin Intravenous (Human).

For full prescribing information, please visit http://www.gammagardliquid.com.

About Alzheimer's Disease

Alzheimer's disease is the most common form of dementia, a clinical condition, which involves the decline or loss of memory and other cognitive abilities. A progressive and ultimately fatal disease marked by severe brain tissue deterioration, Alzheimer's disease initially involves the parts of the brain that control thought, memory and language. The number of new Alzheimer's disease cases diagnosed
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Local veterinary ... in an investigational study of donor stem cells for ... stem cell therapy and has performed clinical stem cell ... study is to determine if a single injection of ... joints can help reduce pain and inflammation in the ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... YORK, June 18 Danube Pharmaceuticals, Inc., a,privately ... development of innovative drugs for ophthalmology, is pleased,to ... MBA as its Chief,Executive Officer., "I am ... this,inflection point in its history as it advances ...
... DIEGO, June 18 Halozyme Therapeutics,Inc. (Nasdaq: ... targeting the extracellular matrix, today,announced that it will ... be held in New York on June 24-26, ... Chief Executive Officer,will present on Wednesday, June 25, ...
... Ovarian Cancer Treatment, Predicting Risk of Gastric ... Non-Small Cell Lung Cancer, In Addition, the Company has Identified Unique microRNA ... the Basis for a Future ... Test for Colon Cancer, New ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5
(Date:10/15/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... mobile commerce market releases photos and video of the recent opening ... 13 th . Gino Pereira , CEO ... investor Mr. Chad A. Verdi rang the bell.  ... investors and employees "for their work and dedication in bringing the ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
(Date:10/14/2014)... A new study published in Cancer Research ... liver and colon cancers—can promote the development of skin ... proliferation and survival of sun-damaged skin cells. , Previously ... seven proteins called sirtuins that help regulate genomic stability ... aging. SIRT6 helps repair DNA damage, which can lead ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... -- (March 11, 2009) -- A Rice University study of ... that everything is bigger in Texas, even the single-celled stuff. ... colony of amoebae clones -- a Texas-sized expanse measuring at ... and featured on cover of the March issue of ...
... support, renewable energy technologies like wind and photovoltaics ... by 2050, according to findings from the International ... Decisions." However, if such technologies are marginalized, its ... This research was presented at a ...
... years, green plants have employed photosynthesis to capture energy ... goal of scientists has been to develop an artificial ... liquid fuels from carbon dioxide and water. Researchers with ... (Berkeley Lab) have now taken a critical step towards ...
Cached Biology News:Texas-sized tract of single-celled clones 2Texas-sized tract of single-celled clones 3New renewables to power 40 per cent of global electricity demand by 2050 2Turning sunlight into liquid fuels 2Turning sunlight into liquid fuels 3
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Inquire...
...
... Isoaspartate Detection Kit is intended for quantitative ... and peptides, which can result from the ... of aspartic acid residues during storage or ... on the monitoring of charge differences for ...
Biology Products: